Red blood cell rigidification during cyclosporin therapy: A possible early warning signal for adverse reactions

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 58, Issue 8, 1998, Pages 617-624

  Hardeman, M R ^a   Meinardi, M M H M ^a   Ince, C ^a   Vreeken, J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Clinical complications; Ektacytometry; Erythrocyte deformability; Immunosuppression; Psoriasis

Indexed keywords

CYCLOSPORIN A;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRY; DOSE RESPONSE; ERYTHROCYTE DEFORMABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS;

EID: 0032431826     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519850186049     Document Type: Article

References (46)

1. 1 Hess AD, Tutschka PJ. Effect of cyclosporin A on human lymphocyte response in vitro (1). J Immunol 1980; 124: 2601-8.
2. 2 Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulary disorders. Drugs 1993; 45: 953-1040.
3. 3 Laupacis A. Complications of cyclosporine therapy; a comparison to azathioprine. Transplant Proc 1983; 15: 2748-53.
4. 4 Adu D, Turney J, Michael J, McMaster P. Hyperkalaemia in cyclosporine treated renal allograft recipients. Lancet 1983; ii: 370-2.
5. 5 Thiel G. Experimental cyclosporine A nephrotoxicity: a summary of the International Workshop (Basle, April 24-26, 1985). Clin Nephrol 1986; 25 Supp. 1: S204-10.
6. 6 Myers BD. Cyclosporine nephrotoxity. Kidney Int 1986; 30: 964-74.
7. 7 Neild GH, Reuben R, Hartley RB, Cameron JS. Glomerular thrombi in renal allografts associated with cyclosporin therapy. J Clin Pathol 1985; 38: 253-8.
8. 8 Vanrenterghem Y, Lerut T, Roels L, Gruwel J, Michielsen P, Gresele P, et al. Thromboembolic complications and hemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; i: 999-1002.
9. 9 Besarab A, Jarell BE, Hirsch S, Carabasi RA. Use of the isolated perfused kidney model to assess the acute pharmalogic effects of cyclosporine and its vehicle, cremophor EL. Transplantation 1987; 44: 195-201.
10. 10 Luke DR, Kasiske BL, Matzke GR, Keane WF. Effects of cyclosporine on the isolated perfused rat kidney. Transplantation 1987; 43: 785-99.
11. 11 ICSH Expert Panel on Blood Rheology. Guidelines for measurement of blood viscosity and erythrocyte deformability. Clin Hemorheol 1986; 6: 439-53.
12. 12 Staübli M, Stone PCW, Straub PW, Stuart J. Evaluation of methods for measuring erythrocyte deformability. Clin Hemorheol 1986; 6: 589-602.
13. 13 Hardeman MR, Goedhart PT, Dobbe JGG, Lettinga KP. Laser-assisted optical rotational cell analyser (L.O.R.C.A.). 1. A new instrument for measurement of various structural hemorheological parameters. Clin Hemorheol 1994; 14: 605-18.
14. 14 Schut NH, Hardeman MR, Wilmink JM. Decrease of erythrocyte deformability in cyclosporin treated renal transplant patients; correction with fish as well as corn oil. Transpl Int 1992; 5 Suppl 1: S536-8.
15. 15 Müller W, Herrmann B. Cyclosporin for psoriasis. N Engl J Med 1979; 301: 555.
16. 16 Agarwal RP, McPherson RA, Threatte GA. Evidence of a cyclosporine binding protein in human erythrocytes. Transplantation 1986; 42: 627-32.
17. 17 Hardeman MR, de Rie MA, Schut NH, Wilmink JM. Impaired erythrocyte deformability in psoriasis patients after treatment with cyclosporin. 7th Eur Conf on Clin Hemorheol, Southampton, 1991. Abstract: Clin Hemorheol 1991; 11: 784.
18. 18 Sentürk UK, Ceylan H, Baskurt OK. Effect of cyclosporin A on red cell deformability. 7th Eur Conf on Clin Hemorheol, Southampton, 1991. Abstract: Clin Hemorheol 1991; 11: 784.
19. 19 Witkamp L, Meinardl MMHM, Bossuyt PMM, van de Kerkhof PCM, Arnold WP, De Hoop D, et al. A multicentre evaluation of the guidelines for the use of cyclosporine A in severe psoriasis. J Eur Acad Dermatol Venereol 1996; 7: 49-58.
20. 20 Akagi H, Reynolds A, Hjielm M. Cyclosporin A and its metabolites, distribution in blood and tissues. J Int Med Res 1991; 19: 1-10.
21. 21 Hardeman MR, Goedhart PT, Schul NH. Laser assisted optical rotational cell analyser (L.O.R.C.A.); II. Red blood cell deformability; elongation index versus cell transit time. Clin Hemorheol 1994; 14: 619-30.
22. 22 Mason J. Renal side-effects of cyclosporin A. Br J Dermatol 1990; 122 Suppl 36: 71-7.
23. 23 Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
24. 24 Fogo A, Hakim RC, Sugiura M, Inagami T, Kon V. Severe endothelial injury in a renal transplant patient receiving cyclosporine. Transplantation 1990; 49: 1190-2.
25. 25 Torras J, Valles J, Sanchez J, Sabate I, Seron D, Carrera M, et al. Prevention of experimental cyclosporine nephrotoxicity by dietary supplementation with LSL 90202: a lysine salt of eicosapentaenoic acid. Nephron 1994; 67: 66-72.
26. 26 Smith SR, Kubacki VB, Rakhit A, Martin LL, Schafer AV, Jasani MK, et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Transplantation 1993; 56: 1422-6.
27. 27 Voss BL, Hamilton KH, Samara ENS, McKee PA. Cyclosporine suppression of endothelial prostacyclin generation. Transplantation 1988; 45: 793-6.
28. 28 Nield GH, Rocchi G, Imberti L, Fumagalli F, Brown Z, Remuzzi G, Williams DG. Effect of cyclosporin A on prostacyclin synthesis by vascular tissue. Thromb Res 1983; 32: 373-9.
29. 29 Homan van der Heide JJ, Bilo HJG, Tegzess AM, Donker AJM. The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients. Transplantation 1990; 49: 523-7.
30. 30 Yoa RG, Corda C, Rapin JR, Santona L, Goudonnet H, Rifle G, et al. Hemorheological benefits of omega-3 polyunsaturated fatty acids on erythrocyte deformability in renal transplanted patients. Clin Hemorheol 1994; 14: 663-75.
31. 31 Schut NH, Bilo HIG, Popp-Snijders C, Goedhart PT, Wilmink JM. Erythrocyte deformability, endothelin levels and renal function in cyclosporin-treated renal transplant recipients: effects of intervention with fish oil and corn oil. Scand Clin Lab Invest 1993; 53: 499-506.
32. 32 Harris KP, Jenkins D, Walls J. Nonsteroidal antiinflammatory drugs and cyclosporin. A potentially serious adverse interaction. Transplantation 1988; 46: 598-9.
33. 33 Mokken FCH, Kedaria M, Henny CHP, Hardeman MR, Gelb AW. The clinical importance of erythrocyte deformability. A hemorheological parameter. Ann Hematol 1992; 64: 113-22.
34. 34 Jandl JH, Greenberg MS, Yonernoto RH, Castle WB. Clinical determination of sites of red cell sequestration in hemolytic anemias. J Clin Invest 1956; 35: 842-6.
35. 35 Nielsen OJ, Mandrup-Poulsen T, Nerup J. Deficiency of erythropoietin is not responsible for the anemia associated with cyclosporin treatment of insulin-dependant diabetis mellitus. J Int Med 1993; 233: 471-5.
36. 36 McGrath LT, Treacy R, McClean E, Brown JH. Oxidative stress in cyclosporin and azathioprine treated renal transplant patients. Clin Chim Acta 1997; 264: 1-12.
37. 37 Wang C, Salahudeen AK. Cyclosporin nephrotoxicity: attenuation by an antioxidant-inhibitor of lipid peroxidation in vitro and in vivo. Transplantation 1994; 58: 940-6.
38. 38 Phair PC, Powell HR, McCredie DA. Lipid abnormalities in red blood cell and plasma phospholipids in cyclosporine-treated heart transplant recipients. Transpl Proc 1994; 26: 3722-6.
39. 39 Palinski W, Torsellini A, Doni L. Influence of platelet activation on erythrocyte deformability. Thromb Haemost 1983; 49: 84-6.
40. 40 Kovacs IB, O'Grady J. Prostacyclin increases filterability of normal and rigidified human red blood cells in vitro. Agents Actions 1984; 14: 306-10.
41. 41 Belch JJF, McLaren M, Anderson J, et al. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostaglandins Leukot Essent Fatty Acids 1985; 17: 1-9.
42. 42 Sipes SL, Weiner CP, Gellhaus TM, Goodspeed JD. Effects of magnesium sulfate infusion upon plasma prostaglandins in preeclampsia and preterm labor. Hypertens Pregn 1994; 13: 293-302.
43. 43 Nozue T, Kobayashi A, Kodama T, Uemasu F, Endoh H, Sako H, Takagi Y. Pathogenesis of cyclosporin-induced hypomagnesia. J Pediatr 1992; 120: 638-40.
44. 44 June CH, Thompson CB, Kennedy MS, Nims J, Thomas ED. Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporin for marrow transplantation. Transplantation 1985; 39: 620-4.
45. 45 Al-Khursani I, Thomas TH, Harrison K, Wilkinson R. Reduced erythrocyte and leukocyte magnesium is associated with cyclosporin treatment and hypertension in renal transplant patients. Nephrol Dial Transpl 1992; 7: 251-5.
46. 46 Dondorp AM, Angus BJ, Hardeman MR, Chotivanich KT, Silamut K, Ruangveerayuth R, et al. Prognostic significance of reduced red blood cell deformability in severe falciparum malaria. Am J Trop Med Hyg 1997; 57: 507-11.